143 unknown, 106 recruiting, 57 completed, 40 not yet recruiting. 129 Phase 2, 81 Not applicable, 51 Phase 1, 47 Phase 3, 20 Phase 4.
Follow The First Affiliated Hospital of Soochow University: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| U69-CART-Cells For R/R T-ALL CXCR4 CCR9 CAR-T - Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma | Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | 12 | 2026-10-25 | 2026-09-02 |
| BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia Ifupinostat Hydrochloride - B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | 15 | 2026-09-01 | 2026-10-02 |
| Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma Sonrotoclax, Glofitamab, Gemcitabine (1000 mg/m2) - Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 39 | 2026-08-20 | 2026-08-19 |
| Cousin vs. Sibling Donors in Haplo-HSCT Hematopoietic Malignancies, Haploidentical Hematopoietic Stem Cell Transplantation | Not yet recruiting | The First Affiliated Hospital of Soochow University | 1000 | 2026-08-01 | 2026-06-23 | |
| A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients Venetoclax, Azacitidine (AZA), Decitabine 20 mg/m²/day for 5 days - Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT) | Not applicable | Not yet recruiting | The First Affiliated Hospital of Soochow University | 42 | 2026-08-01 | 2026-08-19 |
| Safety and Feasibility of FMT for Immune Recovery After HSCT Fecal microbiota transplantation (FMT) - Humoral Immunodeficiency, Hematopoietic Stem Cell Transplantation | Phase 1 / Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 86 | 2026-08-01 | 2026-08-12 |
| U96-CAR-T-Cells For R/R B-ALL U96 - Relapsed or Refractory B Cell Leukemia and Lymphoma | Phase 1 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-07-30 | 2026-05-28 |
| A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Obinutuzumab, Glofitamab, Gemcitabine - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 96 | 2026-07-22 | 2026-07-13 |
| Younger vs. Older Donors in Allo-HSCT: TTE A Target Trial Emulation Study, Donor Age | Not yet recruiting | The First Affiliated Hospital of Soochow University | 5000 | 2026-07-15 | 2026-06-24 | |
| A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen Sotoclax, Carfilzomib, Lenalidomide - Newly Diagnosed Multiple Myeloma, T(11;14) | Phase 4 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 20 | 2026-07-01 | 2026-07-17 |
| Prospective Sample Collection Study for a Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection - Ovarian Neoplasms, Ovarian Cancer | Not yet recruiting | Tongji Hospital | 1000 | 2026-07-01 | 2026-05-18 | |
| Endofaster Robot for Gastroesophageal Submucosal Tumors: A Randomized Controlled Study Robot system, Non-robotic conventional endoscopy - Gastric Submucosal Tumors | Not applicable | Not yet recruiting | The First Affiliated Hospital of Soochow University | 110 | 2026-07-01 | 2026-06-18 |
| TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis TP04HN106, Saline - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Talengen Institute of Life Sciences, Shenzhen, P.R. China. | 60 | 2026-06-04 | 2026-10-02 |
| AI-Integrated Emotional Granularity Training for Resilience and Quality of Life in Colorectal Cancer Survivors Emotional granularity training, Routine Care - Colorectal Cancer (CRC) | Not applicable | Not yet recruiting | The Hong Kong Polytechnic University | 54 | 2026-06-01 | 2026-06-04 |
| CMV-CMI in csCMVi After HSCT Anti-Cytomegalovirus Therapy - Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT) | Recruiting | The First Affiliated Hospital of Soochow University | 40 | 2026-06-01 | 2026-07-07 | |
| Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage Mobile Stroke Unit Management, Standard Management - Nervous System Diseases, Cerebrovascular Disorders | Not applicable | Not yet recruiting | Xuanwu Hospital, Beijing | 706 | 2026-06-01 | 2026-06-24 |
| VA Consolidation in Intermediate-Risk AML Venetoclax and Azacitidine, Cytarabine ± Anthracycline - Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 226 | 2026-06-01 | 2026-08-06 |
| SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS SHR2554/AZA + Overlapped mBUCY, mBUCY conditioning Regimen Group - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 180 | 2026-06-01 | 2026-06-10 |
| SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS SHR2554/AZA + Overlapped TBF, mBUCY conditioning regimen - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 160 | 2026-06-01 | 2026-05-01 |
| VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML Venetoclax (VEN), Azacitidine (AZA), Allo-HSCT - Hypoplastic Acute Myeloid Leukemia, Secondary AML (Adult) | Not applicable | Not yet recruiting | The First Affiliated Hospital of Soochow University | 50 | 2026-06-01 | 2026-06-09 |
Showing 20 of 372. Sign in to see all of them.
Leukemia, Myeloid, Acute (54) · Recurrence (24) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (17) · Multiple Myeloma (16) · Burkitt Lymphoma (11) · Lymphoma, Large B-Cell, Diffuse (11) · Prostatic Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (8) · Lymphoma, B-Cell (7) · Disease (6) · Hematologic Neoplasms (6) · Ischemic Stroke (6) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (6) · Stroke (6) · Cytomegalovirus Infections (5)
Azacitidine (29) · venetoclax (22) · Decitabine (16) · Cyclophosphamide (14) · Cytarabine (13) · Dexamethasone (10) · Rituximab (10) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (8) · fludarabine (8) · Lenalidomide (7) · blinatumomab (7) · Acetylcysteine (6) · Immunotherapy, Adoptive (6) · Observation (6) · Prednisone (6)
China (341) · Australia (1) · Hong Kong (1) · Italy (1)
Xiaowen Tang, Ph.D (9) · Depei Wu (5) · Depei Wu, M.D (5) · Sheng-Li Xue, M.D. (5) · Suning Chen (5) · Xiaojin Wu, Prof. (5) · Depei Wu, M.D., Ph.D. (4) · Xiaowen Tang, Ph.D. (4) · Xiaowen Tang, PhD (4) · Xuefeng He, doctor (4) · Liyan Miao, Ph.D (3) · Liyan Miao, PhD (3) · Rui Li, Dr. (3) · Suning Chen, Professor (3)
PMID 41671463, PMID 33646303, PMID 11926893, PMID 12481731, PMID 15057287, PMID 15509186, PMID 15842354, PMID 16818281, PMID 17057569, PMID 17230614, PMID 17939003, PMID 18089654, PMID 18387377, PMID 18468541, PMID 19117511, PMID 20068171, PMID 20485617, PMID 20833554, PMID 21216553, PMID 21266777, PMID 21463757, PMID 21713321, PMID 22677206, PMID 23013804, PMID 23623832, PMID 24165758, PMID 24374800, PMID 25360316, PMID 25439689, PMID 25566808, PMID 25819594, PMID 25979532, PMID 26104794, PMID 26181032, PMID 26248505, PMID 26341514, PMID 26899273, PMID 26913560, PMID 26990499, PMID 27088376, PMID 2728086, PMID 27763679, PMID 27879257, PMID 28011677, PMID 28314688, PMID 28404761, PMID 28945884, PMID 29035356, PMID 29174310, PMID 29629194